28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials

BACKGROUND: The recent Ebola virus disease (EVD) outbreak in the Democratic Republic of the Congo highlights the sustained threat of EVD morbidity and mortality where healthcare and vaccine delivery are challenging. ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Jakub, Kennedy, Stephen, Mahon, Barbara, Dubey, Sheri, Grant-Klein, Rebecca, Liu, Ken, Hartzel, Jonathan, Coller, Beth-Ann, Welebob, Carolee, Hanson, Mary, Grais, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776050/
http://dx.doi.org/10.1093/ofid/ofaa439.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776050/
http://dx.doi.org/10.1093/ofid/ofaa439.073

Ejemplares similares